The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse G1 side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.
本发明涉及美西利汀(及美西利汀的活性代谢物)的前药,包含这些前药的药物组合物。还提供了用于治疗肌张力疾病的方法,同时减少与美西利汀相关的固有不良G1副作用,增加美西利汀的
生物利用度,并通过上述前药改善美西利汀的药代动力学可重复性。